Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Sarcoma 1Lymphoid 1Head & Neck 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Kidney Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostatic Neoplasms × poly ICLC × Genitourinary × Clear all
NCT05010200 2026-01-07

PGV-Prostate

Icahn School of Medicine at Mount Sinai

Phase 1 Active not recruiting
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT06343077 2024-04-02

Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
114 enrolled
Genitourinary

Prostatic Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT03262103 2022-09-10

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Genitourinary

Prostatic Neoplasms

NCT00694551 2019-10-04

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
29 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡